The emergence of SARS-CoV-2 variants may cause resistance at the immunity level against current vaccines. Some emergent new variants have increased transmissibility, infectivity, hospitalization, and mortality. Since the administration of the first SARS-CoV-2 vaccine to a human in March 2020, there is an ongoing global race against SARS-CoV-2 to control the current pandemic situation. Spike (S) glycoprotein of SARS-CoV-2 is the main target for current vaccine development, which can neutralize the infection. Companies and academic institutions have developed vaccines based on the S glycoprotein, as well as its antigenic domains and epitopes, which have been proven effective in generating neutralizing antibodies. The effectiveness of SARS-CoV-2 vaccines and other therapeutics developments are limited by the new emergent variants at the global level. We have discussed the emergent variants of SARS-CoV-2 on the efficacy of developed vaccines. Presently, most of the vaccines have been tremendously effective in severe diseases. However, there are still noteworthy challenges in certifying impartial vaccines; the stories of re-infections are generating more stressful conditions, and this needs further clinical evaluation.
【저자키워드】 SARS-CoV-2, Vaccine, neutralization, variant, Infectivity, 【초록키워드】 Efficacy, Vaccine development, pandemic, Diseases, Mortality, Immunity, Hospitalization, Vaccines, Neutralizing antibodies, spike, Human, SARS-CoV-2 variant, Infection, SARS-CoV-2 vaccines, SARS-CoV-2 vaccine, Epitopes, Transmissibility, SARS-CoV-2 variants, clinical evaluation, Re-infection, Effectiveness, glycoprotein, S glycoprotein, administration, Re-infections, the vaccines, antigenic, domain, company, variants of SARS-CoV-2, effective, neutralize, the vaccine, conditions, 【제목키워드】 emergence, New,